查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854500

胜肽類抗生素市場依產品、給藥途徑、劑型、來源、應用、最終用途及通路分類－2025-2032年全球預測

Peptide Antibiotics Market by Product, Route Of Administration, Formulation, Source, Application, End Use, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胜肽類抗生素市場規模將達到 120.5 億美元，年複合成長率為 10.09%。

主要市場統計數據
基準年 2024 55.8億美元
預計年份：2025年 61.5億美元
預測年份：2032年 120.5億美元
複合年成長率 (%) 10.09%

全面概述胜肽類抗生素的發展機遇，涵蓋科學機制、製劑管道和商業性考量等各個面向。

肽類抗生素兼具分子特異性且多樣化的製劑管道，在抗菌藥物領域中佔有舉足輕重的地位。這些藥物以桿菌肽、粘菌素、Daptomycin和多粘菌素B等成熟分子為代表，廣泛應用於從急性臨床治療到獸醫實踐和食品保藏等多種領域。它們通常具有膜溶解或細胞壁破壞的特性，使其成為一線治療藥物和新型類似物開發的理想載體。此外，不斷演變的抗藥性模式和日益成長的抗菌藥物管理意識，也提升了胜肽類藥物在尋求差異化療效和獨特監管管道的藥物組合中的策略重要性。

生產製造和配方方面的考量是商業性可行性的核心。從肌肉注射、靜脈注射到口服和外用，每種給藥途徑都需要不同的研發和監管策略，而注射劑、粉劑或外用製劑的選擇直接影響低溫運輸、穩定性以及給藥策略。天然胜肽與合成胜肽來源的差異進一步影響成本結構、智慧財產權策略和規模化生產時間表。在這些相互交織的動態中，相關人員必須協調臨床療效要求與實際的供應鏈、分銷管道和最終用途需求，才能將創新轉化為診所、醫院和獸醫診所都能使用的治療方法。

總之，引言部分闡述了胜肽類抗生素的科學前景和運作複雜性。在這個快速發展的領域，領導者需要從分子創新、製劑科學、監管現實和通路物流等觀點，才能製定出具有韌性且以機會為導向的策略。

識別並順應正在重新定義肽類抗生素臨床和商業性方式的科學創新、監管收緊和分銷管道轉變。

由於科學、監管和市場力量的共同作用，胜肽類抗生素的模式正在發生顯著變化。胜肽工程技術的進步，包括對雙親性區域的標靶化和穩定化技術，拓寬了某些分子的治療窗口，並實現了更有效的局部和注射劑型。同時，遞送技術的進步，例如延長保存期限的冷凍乾燥製劑和最佳化快速復溶的溶液製劑，降低了臨床應用門檻，並促進了更廣泛的門診病人和獸醫應用。這些技術進步正在加速從傳統使用模式到標靶應用模式的轉變，尤其是在抗藥性和標靶療效至關重要的領域。

政策和法規環境也正在改變企業的策略重點。對抗菌藥物管理日益嚴格的審查以及修訂後的動物用藥品指南，迫使企業重新評估標籤、應用策略和數據生成計劃。這些監管變化也促使大型臨床系統和獸醫醫院網路改變採購行為，更加重視那些能夠展現出健全的品質體系、可複製的供應鏈以及快速分銷管道（例如醫院藥房和線上藥房平台）的供應商。同時，食品保鮮領域的需求面發展，推動了人們對兼具療效和明確安全性的胜肽製劑的興趣，促進了食品科學家和抗菌藥物研發人員之間的跨領域合作。

總體而言，這些轉變正在催生新的經營模式，例如製造商與合約研究組織之間的策略聯盟、向製劑和低溫運輸物流的垂直整合，以及與分銷合作夥伴的新型商業安排。能夠將研究重點與監管預期和通路能力結合的機構，將更有利於把技術進步轉化為持續的臨床和商業性成功。

評估近期美國關稅調整對胜肽類抗生素採購、生產、分銷和投資決策的實際營運和策略影響

2025年新關稅的實施，為胜肽類抗生素的採購和生產核算帶來了新的複雜性。胜肽類抗生素合成和純化過程中使用的原料、中間體和專用試劑，在到達製劑生產地之前往往需要跨越多個國家/地區，而不斷上漲的關稅使得繪製供應商網路圖和評估各國成本促進因素變得尤為重要。依賴跨境供應活性藥物原料藥和輔料的生產商面臨更高的到岸成本和更大的運輸延誤風險，迫使他們重新調整籌資策略和庫存管理方式。

對此，一些商業策略正在湧現。首先，企業越來越傾向將關鍵生產環節在地化，或選擇其他區域供應商，以減輕關稅負擔，同時維持品質標準。其次，企業優先考慮減少對溫控貨物依賴的配方選擇，因為溫控貨物的關稅會增加物流成本。冷凍乾燥注射劑和穩定的外用製劑正重新受到歡迎，因為它們可以降低關稅和低溫運輸的綜合成本。第三，分銷通路策略正在演變。企業正在重新評估醫院藥局和直接供貨協議，以維持利潤率並確保供應連續性，同時也在評估線上藥局和零售藥局在最後一公里配送方面的成本效益。

財務規劃和投資決策也受到間接影響。關稅制度帶來的不確定性促使企業謹慎地將資金配置到待開發區製造計劃上，並加速了對製造外包關係的興趣，因為合約製造可以轉移部分關稅和物流風險。同時，這些動態迫使企業積極與貿易和監管機構溝通，以確保明確的指導，並為關鍵的公共衛生產品爭取可能的豁免。最終，有效的應對措施很可能是將戰術性調整（例如庫存平衡和供應商多元化）與戰略舉措相結合，以增強韌性而非單純追求成本來重組價值鏈。

深入的分析細分洞察，將產品概況、給藥途徑、製劑選擇、產地、應用、最終用途和分銷動態聯繫起來

領先的胜肽類抗生素在產品層面的差異化決定了其臨床定位和生命週期策略。桿菌肽在某些局部和局部應用方面仍然十分重要，而粘菌素和多粘菌素B則常用於治療複雜的抗藥性革蘭氏陰性感染疾病，從而推動了專門的臨床方案和管理框架的發展。Daptomycin的活性特徵使其適用於其他藥物療效欠佳的全身性行為感染，這有助於醫院在藥物配方談判中爭取最佳療效，並有助於產生針對特定治療路徑的證據。這些差異影響研發投資的優先順序、適應症擴大策略以及與專科藥局和醫院的合作機會。

不同的給藥途徑造就了截然不同的商業和監管路徑。肌肉注射和靜脈注射途徑推動了無菌注射劑的研發，強調無菌生產和低溫運輸物流。口服給藥在生物有效性和酵素穩定性方面面臨製劑方面的挑戰，但為門診病人和零售藥房提供了極具吸引力的機會。局部給藥可加速產品上市速度，例如用於傷口護理和某些獸醫適應症，同時為診所和零售環境中的創新包裝和供應方案提供了可能。不同給藥途徑之間的轉換通常需要針對性地重新配製製劑並補充臨床證據，從而影響研發進度和資源分配。

製劑的選擇對產品競爭和市場准入至關重要。注射劑分為凍乾粉劑和溶液劑，兩者在穩定性、復溶時間和儲存需求方面各有優劣。凍乾粉劑可以減少對低溫運輸的依賴，而溶液劑在急診環境中更方便。粉劑給藥方式靈活，且根據具體應用情況，保存期限更長。乳膏和軟膏等外用製劑必須在滲透性、潛在刺激性和患者依從性之間取得平衡，所有這些因素都會影響其在診所和獸醫機構的接受度。這些製劑選擇會對生產投資、包裝設計和分銷管道的選擇產生影響。

天然胜肽與合成胜肽的來源會影響成本、智慧財產權和規模化生產。天然胜肽具有較高的安全性和已確立的生物活性，但易受供應限制和個體差異的影響。合成路線可以進行結構最佳化和獨特的修飾，從而支援差異化聲明和更長的獨家銷售期，但可能需要更多的領先製程開發。天然胜肽與合成胜肽的選擇也會影響監管文件和供應商的選擇。

其用途涵蓋臨床、食品保藏和獸醫等領域，每種用途都有其獨特的證據和監管要求。臨床用途需要嚴格的安全性和有效性數據，並與醫院配方委員會和藥品管理計畫密切合作。食品保藏用途需要證明其在食品基質中的安全性以及與加工流程的兼容性。獸醫用途需要靈活的劑型，並透過獸醫診所和專業零售管道進行分銷。最終使用者環境（診所、醫院和獸醫診所）決定了採購週期、採購管理和首選分銷合作夥伴。

包括醫院藥局、線上藥局和零售藥局在內的分銷管道，各自呈現出不同的商業化動態。醫院藥局傾向於簽訂批量合約、建立嚴格的品質系統和整合物流，而線上藥局則強調門診病人處方箋和專科藥品的覆蓋範圍和便利性。零售藥局支援照護現場，但需要針對特定門診病人的產品展示和溝通方式。每個通路都需要不同的商業條款、監管支援材料和物流規劃，因此，將通路策略與產品、途徑、配方、供應來源、應用和最終用途相匹配，對於成功打入市場至關重要。

了解亞太、歐洲、中東和美洲地區推動製造業、監管和商業化優先事項的區域性要務。

區域動態正在塑造投資、生產和商業化最有利的地區。在美洲，完善的臨床基礎設施意味著三級醫院和專科診所對先進胜肽類療法的需求十分旺盛。同時，獸醫網路和某些食品供應鏈為具有良好安全性的胜肽類藥物提供了拓展市場的機會，從而促進了臨床和農業相關人員之間的跨領域合作。

監管協調和醫療體係成熟度的差異正在影響歐洲、中東和非洲的打入市場策略。歐洲監管機構日益重視抗生素管理和與目標適應症相關的有條件核准，這影響著資料收集的優先事項和標籤策略。在中東和非洲部分地區，藥品可及性和供應鏈的穩健性仍然是關鍵考量因素，市場機會往往取決於建立值得信賴的區域夥伴關係關係，以及確保產品在不同的儲存條件下保持穩定。這些區域差異要求企業採用靈活的商業模式，在集中式生產和在地化分銷解決方案之間取得平衡。

亞太地區兼具快速成長的需求、大規模的生產能力和多元化的管理體制。該地區的多個市場擁有旺盛的臨床需求和強大的受託製造生態系統，為區域製造中心提供了發展機會。然而，監管預期、價格敏感度和通路結構（從醫院採購聯盟到強大的零售藥局網路）的差異，要求企業制定細緻的市場准入計畫。在所有地區，製劑穩定性、給藥途徑和分銷管道設計必須與當地的監管和臨床實際情況相符，這對於實現產品的持續推廣至關重要。

業界領導企業如何將技術、製造和商業能力結合，從而在胜肽類抗生素領域打造強大且差異化的價值提案

肽類抗生素領域的主要企業透過整合技術深度、卓越的生產能力和策略通路夥伴關係來脫穎而出。投資於高品質無菌生產、先進凍乾技術和高效低溫運輸的企業，物流更好地服務那些將供應可靠性放在首位的醫院和診所客戶。研發領導者致力於提高胜肽的穩定性、降低毒性，並設計類似物以對抗抗藥性病原體，同時也探索符合監管要求和限制適應症的監管途徑。

將產品、病患支援和分銷結合的整合價值提案對於商業性差異化而言正變得日益重要。能夠為外用和注射產品提供全面包裝、管理培訓材料以及獸醫用藥指南的公司往往能獲得更有利的採購結果。製造商、合約研究與受託製造廠商合作夥伴（尤其是醫院藥房和線上藥房）之間的策略聯盟是無需過多資本支出即可快速擴大規模的常用機制。

製造創新和供應鏈韌性也是通用的主題。那些建立冗餘供應商資格認證、投資區域填充和包裝能力並採用模組化製造方法的企業，更能抵禦關稅和貿易中斷的影響。智慧財產權策略透過許可和合資企業保護合成強化劑和新型配方，同時促進合作開發，已被證明能有效加速市場准入，因為嚴格的合規性和透明的安全報告對於建立臨床醫生、獸醫和採購決策者之間的信任仍然至關重要。

領導者可以採取切實可行的策略步驟來降低供應風險、加速臨床應用，並建立支援長期成長的彈性分銷模式。

產業領導者應優先採取一系列協調一致的行動，以降低營運風險並最大限度地發揮臨床效益。首先，供應商網路多元化並選擇合格的區域合作夥伴，將有助於降低跨境關稅壓力和物流中斷帶來的風險。此外，還應有針對性地投資於配方策略，優先採用凍乾和其他穩定性增強劑型，從而減少對溫度敏感型運輸的依賴，並實現產品在診所、醫院和獸醫機構的更廣泛分銷。

其次，我們正在加速開發合成胜肽平台，該平台能夠進行結構最佳化和智慧財產權保護，同時在適當情況下開發天然產物管道，以充分利用已建立的安全特性。這種平行開發模式可以加快特定應用產品的上市速度，並在原料來源不確定時提供更多選擇。第三，我們正在建構策略性經銷夥伴關係。透過建構線上藥局履約和零售藥局展示能力，我們正透過與醫院藥局合作，利用數據主導的價值提案，擴大產品覆蓋範圍並創造穩定的收入來源。

第四，透過積極調整臨床證據計畫以符合不斷更新的指南，並在實際應用環境中支持抗菌藥物管理項目，加強與監管機構的溝通和管理。投資於上市後監測基礎設施和透明安全報告的公司更有可能被製劑委員會更快接受。第五，採用靈活的生產模式，例如契約製造夥伴關係和模組化生產能力，以管理資本風險並提高對需求變化的應對力。最後，針對動物用藥品和食品安全客戶開發有針對性的商業組合方案，重點是安全性、易用性和整體擁有成本 (TCO) 優勢。

一個穩健的混合方法研究框架，整合了主要相關人員訪談、二手科學和監管研究、供應鏈圖譜繪製和情境分析。

支撐這些洞見的研究結合了多種互補方法，以確保其有效性、可靠性和實際相關性。主要研究包括對臨床醫生、醫院藥劑師、獸醫、採購負責人和生產主管進行結構化訪談，以深入了解使用案例需求、採購動態和生產限制。次要研究包括對同行評審的科學文獻、監管指導文件和產品標籤進行系統性回顧，將技術和監管視角建立在權威資訊來源之上。這些要素經過三角驗證，以減少偏差並檢驗相關人員群體中湧現的主題。

定量營運映射分析考察了原料藥和輔料的供應鏈管道，識別出影響到岸成本和前置作業時間的常見轉運點和物流瓶頸。定性主題分析捕捉了監管機構的態度、採用新型製劑的意願以及終端用戶的管道偏好。此外，還進行了情境規劃，模擬了因關稅導致的供應中斷的替代應對方案，並在各種監管條件下對製劑和分銷策略進行了壓力測試。

為確保透明度，調查方法詳細說明了訪談樣本框架、二手資料納入標準以及用於綜合分析研究結果的方法。研究方法也指出了其限制。監管政策的快速變化和意料之外的貿易政策轉變可能會改變特定實踐建議的相關性，而不斷湧現的臨床數據也可能隨著時間的推移改變治療立場。綜合調查方法可為商業性和技術領導者提供可靠且可操作的結論。

策略綜合分析重點闡述如何協調製劑、生產、分銷和監管參與，以實現胜肽類抗生素的臨床和商業性潛力。

總之，胜肽類抗生素是具有重要策略意義的治療藥物，能夠滿足臨床需求、獸醫應用以及食品保鮮等輔助用途。分子創新、製劑策略和分銷管道設計之間的相互作用將決定哪些產品能夠獲得臨床應用和商業性成功。從抗菌藥物管理的期望到關稅造成的供應鏈複雜性，目前的壓力要求我們採取綜合應對措施，將技術發展與切實可行的營運規劃相結合。

能夠使其配方選擇、生產佈局和經銷夥伴關係與監管實際情況相符的企業，可以降低業務中斷的風險，同時推動產品在醫院、診所和獸醫機構的普及應用。投資於能夠增強穩定性的合成平台和配方，可以提升產品差異化優勢和長期價值；而積極主動地與監管機構溝通並提供支持，則有助於加速產品被市場接受。透過實施建議的營運和商業措施，相關人員可以抵禦眼前的挑戰，並為滿足不斷變化的臨床需求和跨領域需求做好準備。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 增加合成胜肽最佳化方面的投資，以對抗多重抗藥性菌株
  • 提高口服胜肽類抗生素的使用率以提高患者依從性
  • 建構人工智慧驅動的胜肽設計平台以加速藥物發現
  • 生技公司與學術機構進行策略合作，以加強胜肽類抗生素研發管線。
  • 新型環肽類抗生素核准用於治療院內感染疾病
  • 利用奈米載體遞送系統提高胜肽類抗生素的穩定性和生物利用度的新方法

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 胜肽類抗生素市場（依產品分類）

  • 桿菌胜肽
  • 黏菌素
  • Daptomycin
  • 多粘菌素B

9. 依給藥途徑分類的胜肽類抗生素市場

  • 肌肉內注射
  • 靜脈
  • 口服
  • 局部的

第10章 以劑型分類的胜肽類抗生素市場

  • 注射
    • 凍乾粉
    • 解決方案
  • 粉末
  • 局部製劑
    • 奶油
    • 軟膏

第11章 胜肽類抗生素市場（依來源分類）

  • 自然的
  • 合成

第12章 依應用分類的胜肽類抗生素市場

  • 臨床應用
  • 食品保藏
  • 獸用

13. 依最終用途分類的胜肽類抗生素市場

  • 診所
  • 醫院
  • 動物診所

第14章 胜肽類抗生素市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章 各地區胜肽類抗生素市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 胜肽類抗生素市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國胜肽類抗生素市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Astellas Pharma Inc.
    • F. Hoffmann-La Roche Ltd.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Fresenius Kabi AG
    • Hikma Pharmaceuticals PLC
Product Code: MRR-205091A88A0F

The Peptide Antibiotics Market is projected to grow by USD 12.05 billion at a CAGR of 10.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.58 billion
Estimated Year [2025] USD 6.15 billion
Forecast Year [2032] USD 12.05 billion
CAGR (%) 10.09%

A comprehensive foundational overview that synthesizes scientific mechanisms, formulation pathways, and commercial considerations shaping opportunities for peptide antibiotics

Peptide antibiotics occupy a distinct and increasingly important position within the broader antimicrobial ecosystem, combining molecular specificity with versatile formulation pathways. These agents, represented across established molecules such as Bacitracin, Colistin, Daptomycin, and Polymyxin B, are applied in diverse settings from acute clinical care to veterinary practice and targeted food-preservation applications. Their mechanisms-often membranolytic or cell-wall disruptive-make them valuable both as primary therapeutics and as scaffolds for novel analogue development. Moreover, evolving resistance patterns and an intensified focus on stewardship have elevated the strategic importance of peptides in portfolios seeking differentiated efficacy profiles and clearer regulatory pathways.

Manufacturing and formulation considerations are central to commercial viability. Routes of administration ranging from intramuscular and intravenous delivery to oral and topical applications require distinct development and regulatory approaches, and the choice of injectable, powder, or topical formulations directly influences cold-chain, stability, and dosing strategies. Source differentiation between natural and synthetic peptides further shapes cost structures, intellectual property strategies, and scale-up timelines. Across these intersecting dynamics, stakeholders must reconcile clinical performance imperatives with pragmatic supply-chain, distribution channel, and end-use requirements so that innovations translate into accessible therapies for clinics, hospitals, and veterinary clinics alike.

In short, the introduction establishes both the scientific promise and the operational complexity of peptide antibiotics. Leaders need a view that integrates molecular innovation, formulation science, regulatory realities, and channel logistics to craft resilient, opportunity-focused strategies in this rapidly evolving domain.

Identify and align with the converging scientific innovations, regulatory tightening, and distribution shifts that are redefining how peptide antibiotics reach clinical and commercial use

The landscape for peptide antibiotics is undergoing transformative shifts driven by converging scientific, regulatory, and market forces. Advances in peptide engineering, including targeted modification of amphipathic regions and stabilization techniques, have expanded the therapeutic window for several molecules and enabled more robust topical and injectable formulations. At the same time, improvements in delivery science-such as lyophilized formulations that extend shelf life and solution formats optimized for rapid reconstitution-are reducing barriers to hospital adoption and enabling broader outpatient and veterinary use. These technical gains are accelerating a transition from legacy usage patterns toward purpose-built applications in settings where resistance management and targeted efficacy matter most.

Policy and regulatory environments are also reshaping strategic priorities. Heightened scrutiny of antimicrobial stewardship and revised guidelines for veterinary applications are prompting firms to rethink labeling, indication strategies, and data-generation plans. This regulatory tightening is accompanied by shifts in procurement behavior among large clinical systems and veterinary networks, which are increasingly prioritizing suppliers that can demonstrate robust quality systems, reproducible supply chains, and responsive distribution channels such as hospital pharmacies and curated online pharmacy platforms. At the same time, demand-side developments in food preservation are promoting interest in peptide formulations that combine efficacy with clear safety profiles, prompting cross-sector collaborations between food scientists and antimicrobial developers.

Collectively, these shifts are catalyzing new business models: strategic alliances between manufacturers and contract development organizations, vertical integration into formulation and cold-chain logistics, and novel commercial agreements with distribution partners. Organizations that align research priorities with regulatory expectations and channel capabilities will be best positioned to convert technical advances into sustained clinical and commercial success.

Assess the practical operational and strategic consequences of recent U.S. tariff changes on sourcing, manufacture, distribution, and investment decisions in peptide antibiotics

The implementation of new tariff measures in 2025 has introduced a fresh layer of complexity to the sourcing and manufacturing calculus for peptide antibiotics. Raw materials, intermediates, and specialized reagents used in peptide synthesis and purification often cross multiple borders before reaching formulation sites, and elevated duties have increased the importance of mapping supplier networks and assessing country-level cost drivers. Manufacturers reliant on cross-border supply of active pharmaceutical ingredients and excipients face rising landed costs and greater exposure to transit delays, requiring a recalibration of procurement strategies and inventory policies.

In response, several operational consequences have emerged. First, there is increased motivation to localize critical stages of production or to qualify alternative regional suppliers that reduce tariff exposure while maintaining quality standards. Second, companies are prioritizing formulation choices that limit dependency on temperature-sensitive freight where tariffs compound logistics costs; lyophilized injectables and stable topical formulations are gaining renewed attention as they can mitigate combined tariff and cold-chain expenses. Third, distribution channel strategies are evolving: hospital pharmacies and direct-supply agreements are being re-evaluated to preserve margins and ensure continuity, while online and retail pharmacies are being assessed for cost-efficient last-mile delivery.

Financial planning and investment decisions are also being affected indirectly. The uncertainty introduced by tariff regimes is prompting greater caution in capital allocation for greenfield manufacturing projects and accelerating interest in contract manufacturing relationships that transfer some tariff and logistics risk. At the same time, these dynamics are compelling firms to engage proactively with trade and regulatory authorities to secure clarifying guidance and potential exemptions for critical public-health products. Ultimately, effective responses blend tactical adjustments-such as inventory smoothing and supplier diversification-with strategic moves to reconfigure value chains around resilience rather than purely on cost.

Deep analytical segmentation insights that connect product profiles, administration routes, formulation choices, source origins, applications, end-use contexts, and distribution dynamics

Product-level differentiation among key peptide antibiotics shapes clinical positioning and lifecycle strategies. Bacitracin remains relevant in certain topical and localized applications, whereas Colistin and Polymyxin B are often reserved for complex, resistant Gram-negative infections, driving specialized clinical protocols and stewardship frameworks. Daptomycin's activity profile supports usage in systemic infections where other agents are less effective, informing hospital formulary negotiations and pathway-specific evidence generation. These distinctions influence prioritization of R&D investment, label expansion strategies, and partnership opportunities with specialty pharmacies and hospitals.

Routes of administration create distinct commercial and regulatory trajectories. Intramuscular and intravenous pathways drive demand for sterile injectable development and place premium importance on aseptic manufacturing and cold-chain logistics. Oral administration presents formulation challenges related to bioavailability and enzymatic stability but offers attractive outpatient and retail pharmacy opportunities. Topical delivery provides a faster path to market for applications such as wound care and certain veterinary indications, while enabling creative packaging and supply arrangements for both clinic and retail settings. Transitioning between routes often requires targeted reformulation and additional clinical evidence, which affects timelines and resource allocation.

Formulation choices are central to product competitiveness and access. Injectable formats split into lyophilized powder and solution presentations, each with trade-offs in stability, reconstitution time, and storage needs; lyophilized options can reduce cold-chain dependency while solution formats offer convenience for acute-care settings. Powder formulations enable flexible dosing and extended shelf life for some use cases. Topical formulations that take the form of creams or ointments must balance penetration, irritation potential, and patient adherence, all of which influence acceptance among clinics and veterinary clinics. These formulation decisions cascade into manufacturing investments, packaging design, and distribution channel selection.

Source differentiation between natural and synthetic peptides impacts cost, intellectual property, and scalability. Natural peptides can offer favorable safety and established biological activity but may carry supply constraints and variability. Synthetic routes enable structural optimization and proprietary modifications, supporting differentiated claims and extended exclusivity, yet they may require higher upfront process development. The choice between natural and synthetic also shapes regulatory dossiers and supplier selection.

Applications span clinical use, food preservation, and veterinary use, each with distinct evidence and regulatory requirements. Clinical indications demand rigorous safety and efficacy data and close alignment with hospital formulary committees and stewardship programs. Food preservation applications require demonstration of safety in food matrices and compatibility with processing workflows. Veterinary applications call for flexible dosing formats and distribution through veterinary clinics and specialized retail channels. End-use environments-clinics, hospitals, and veterinary clinics-determine procurement cycles, purchasing controls, and preferred distribution partners.

Distribution channels including hospital pharmacy, online pharmacy, and retail pharmacy introduce different commercialization dynamics. Hospital pharmacies tend to favor volume agreements, stringent quality systems, and integrated logistics, whereas online pharmacies provide reach and convenience for outpatient prescriptions and specialty needs. Retail pharmacies support point-of-care access but require product presentation and consumer-directed communications tailored to lay users. Each channel necessitates different commercial terms, regulatory support materials, and logistics planning, and aligning channel strategy to product, route, formulation, source, application, and end use is critical for successful market penetration.

Understand regional imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate manufacturing, regulatory, and commercialization priorities

Regional dynamics are shaping where investment, manufacturing, and commercialization efforts are most productive. In the Americas, clinical infrastructure is sophisticated and demand for advanced peptide therapeutics is pronounced in tertiary hospitals and specialized clinics, which raises expectations for sterile injectable supply chains and post-market surveillance. At the same time, veterinary networks and certain food chains present extension opportunities for peptides with demonstrated safety profiles, prompting cross-disciplinary engagement between clinical and agricultural stakeholders.

Across Europe, the Middle East & Africa, regulatory harmonization and diverse health-system maturity influence go-to-market strategies. European regulators increasingly emphasize antimicrobial stewardship and conditional approvals tied to targeted indications, which shapes data-generation priorities and label strategies. In parts of the Middle East and Africa, access and supply-chain robustness remain critical considerations, and opportunities often hinge on establishing reliable regional partnerships and ensuring product stability under varied storage conditions. These regional contrasts require adaptive commercial models that balance centralized manufacturing with localized distribution solutions.

The Asia-Pacific region presents a mix of rapid demand growth, significant manufacturing capacity, and diverse regulatory regimes. Several markets within the region combine high-volume clinical demand with strong contract-manufacturing ecosystems, offering opportunities for regional production hubs. However, variations in regulatory expectations, price sensitivity, and channel structures-ranging from hospital procurement consortia to robust retail pharmacy networks-necessitate nuanced entry plans. Across all regions, alignment of formulation stability, route of administration, and distribution channel design with local regulatory and clinical realities is essential to unlocking sustained adoption.

How industry leaders are combining technical, manufacturing, and commercial capabilities to create resilient, differentiated value propositions in peptide antibiotics

Leading companies in the peptide antibiotic space are differentiating through a combination of technical depth, manufacturing excellence, and strategic channel partnerships. Firms investing in high-quality aseptic production, advanced lyophilization capabilities, and validated cold-chain logistics are better positioned to serve hospital and clinic customers who prioritize supply reliability. R&D leaders are concentrating on enhancing peptide stability, reducing toxicity profiles, and engineering analogues that target resistant pathogens, while simultaneously seeking regulatory pathways that recognize stewardship imperatives and limited-use indications.

Commercial differentiation increasingly involves integrated value propositions that combine product, patient support, and distribution. Companies that can offer comprehensive packaging for topical and injectable products, alongside training materials for stewardship and dosing guides for veterinary practitioners, tend to secure more favorable procurement outcomes. Strategic collaborations between manufacturers, contract development and manufacturing organizations, and distribution partners-especially hospital pharmacies and curated online pharmacies-are common mechanisms to scale quickly without overextending capital expenditure.

Innovation in manufacturing methodologies and supply-chain resilience is also a common theme. Organizations building redundant qualification of suppliers, investing in regional fill-finish capacity, and leveraging modular manufacturing approaches can better absorb tariff and trade disruptions. Intellectual property strategies that protect synthetic enhancements and novel formulations while enabling collaborative development through licensing or joint ventures are proving effective at accelerating market access. Finally, performance in regulatory engagement and post-market surveillance differentiates market leaders, since rigorous compliance and transparent safety reporting remain critical to building trust among clinicians, veterinarians, and procurement decision-makers.

Actionable strategic steps for leaders to reduce supply risk, accelerate clinical adoption, and build resilient distribution models that support long-term growth

Industry leaders should prioritize a set of coordinated actions that jointly reduce operational risk and maximize clinical impact. First, diversify supplier networks and qualify regional partners to mitigate exposure to cross-border tariff pressures and logistical disruptions. This approach should be complemented by targeted investments in formulation strategies-favoring lyophilized and other stability-enhancing formats-that reduce dependence on temperature-sensitive transport and enable broader distribution across clinics, hospitals, and veterinary clinics.

Second, accelerate development of synthetic peptide platforms that enable structural optimization and protectable IP, while also running parallel development of natural-product pathways where appropriate to leverage established safety profiles. Such parallel tracks can reduce time-to-market for specific applications and provide options in the face of sourcing volatility. Third, cultivate strategic distribution partnerships. Engaging hospital pharmacies with data-driven value propositions, while building capabilities for online pharmacy fulfillment and retail pharmacy presentation, will broaden access and create resilient revenue streams.

Fourth, strengthen regulatory and stewardship engagement by proactively aligning clinical evidence plans with evolving guidance and by supporting antimicrobial stewardship programs in deployment settings. Firms that invest in post-market surveillance infrastructure and transparent safety reporting will see faster acceptance among formulary committees. Fifth, embrace flexible manufacturing models, including contract manufacturing partnerships and modular capacity, to manage capital exposure and increase responsiveness to demand shifts. Finally, develop targeted commercial bundles for veterinary and food-preservation customers that emphasize safety, handling simplicity, and total cost-of-ownership benefits-an approach that can diversify revenue while addressing public-health and regulatory concerns.

A robust mixed-methods research framework integrating primary stakeholder interviews, secondary scientific and regulatory review, supply-chain mapping, and scenario analysis

The research underpinning these insights combined multiple complementary methods designed to ensure validity, reliability, and practical relevance. Primary research consisted of structured interviews with clinicians, hospital pharmacists, veterinary practitioners, procurement officers, and manufacturing executives, enabling a deep understanding of use-case requirements, procurement dynamics, and manufacturing constraints. Secondary research involved systematic review of peer-reviewed scientific literature, regulatory guidance documents, and product labels to ground technical and regulatory observations in authoritative sources. These elements were triangulated to reduce bias and validate emergent themes across stakeholder groups.

Quantitative operational mapping examined supply-chain pathways for active pharmaceutical ingredients and excipients, identifying common transshipment points and logistics choke points that influence landed costs and lead times. Qualitative thematic analysis captured attitudes toward stewardship, willingness to adopt novel formulations, and channel preferences among end users. Scenario planning exercises were employed to model alternative responses to tariff-driven supply disruptions and to stress-test formulation and distribution strategies under varying regulatory conditions.

To ensure transparency, the methodology includes details on sample frames for interviews, inclusion criteria for secondary sources, and the analytical techniques used to synthesize findings. Limitations are acknowledged: rapid regulatory changes or unexpected trade-policy shifts can alter the relevance of specific operational recommendations, and emergent clinical data may shift therapeutic positioning over time. Nevertheless, the combined methodological approach supports robust, actionable conclusions for commercial and technical leaders.

A strategic synthesis highlighting how formulation, manufacturing, distribution, and regulatory engagement must align to realize the clinical and commercial potential of peptide antibiotics

In conclusion, peptide antibiotics represent a strategically important class of therapeutics that bridge clinical needs, veterinary applications, and ancillary uses such as food preservation. The interplay between molecular innovation, formulation strategy, and distribution channel design determines which products achieve clinical traction and commercial resilience. Current pressures-from antimicrobial stewardship expectations to tariff-induced supply-chain complexity-require integrated responses that combine technical development with pragmatic operational planning.

Organizations that align formulation choices, manufacturing footprints, and distribution partnerships with regulatory realities will mitigate exposure to disruption while enhancing adoption among hospitals, clinics, and veterinary clinics. Investing in synthetic platforms and stability-enhancing formulations will improve differentiation and long-term value, while proactive regulatory engagement and stewardship support will accelerate acceptance. By implementing the recommended operational and commercial measures, stakeholders can navigate immediate headwinds and position themselves to capitalize on evolving clinical needs and cross-sector demand.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increased investment in synthetic peptide optimization to combat multidrug resistant bacterial strains
  • 5.2. Rising adoption of oral peptide antibiotic formulations for improved patient compliance
  • 5.3. Implementation of AI-driven peptide design platforms for accelerated drug discovery
  • 5.4. Strategic partnerships between biotech firms and academic institutions to enhance peptide antibiotic pipelines
  • 5.5. Regulatory approvals of novel cyclic peptide antibiotics for hospital-acquired infection treatment
  • 5.6. Emerging use of nanocarrier delivery systems to enhance peptide antibiotic stability and bioavailability

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptide Antibiotics Market, by Product

  • 8.1. Bacitracin
  • 8.2. Colistin
  • 8.3. Daptomycin
  • 8.4. Polymyxin B

9. Peptide Antibiotics Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Topical

10. Peptide Antibiotics Market, by Formulation

  • 10.1. Injectable
    • 10.1.1. Lyophilized Powder
    • 10.1.2. Solution
  • 10.2. Powder
  • 10.3. Topical Formulation
    • 10.3.1. Cream
    • 10.3.2. Ointment

11. Peptide Antibiotics Market, by Source

  • 11.1. Natural
  • 11.2. Synthetic

12. Peptide Antibiotics Market, by Application

  • 12.1. Clinical Use
  • 12.2. Food Preservation
  • 12.3. Veterinary Use

13. Peptide Antibiotics Market, by End Use

  • 13.1. Clinics
  • 13.2. Hospitals
  • 13.3. Veterinary Clinics

14. Peptide Antibiotics Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Peptide Antibiotics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Peptide Antibiotics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Peptide Antibiotics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Merck & Co., Inc.
    • 18.3.2. Pfizer Inc.
    • 18.3.3. Astellas Pharma Inc.
    • 18.3.4. F. Hoffmann-La Roche Ltd.
    • 18.3.5. Sanofi S.A.
    • 18.3.6. GlaxoSmithKline plc
    • 18.3.7. Teva Pharmaceutical Industries Ltd.
    • 18.3.8. Sandoz International GmbH
    • 18.3.9. Fresenius Kabi AG
    • 18.3.10. Hikma Pharmaceuticals PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. PEPTIDE ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. PEPTIDE ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PEPTIDE ANTIBIOTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY BACITRACIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY BACITRACIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY BACITRACIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY BACITRACIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY BACITRACIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY BACITRACIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COLISTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COLISTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COLISTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COLISTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COLISTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COLISTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DAPTOMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DAPTOMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DAPTOMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DAPTOMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY OINTMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY OINTMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY NATURAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICAL USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICAL USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICAL USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICAL USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICAL USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICAL USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FOOD PRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FOOD PRESERVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FOOD PRESERVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FOOD PRESERVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FOOD PRESERVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY FOOD PRESERVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL FORMULATION, 2018-2024 (USD MILLIO